XBiotech Overview
- Status
- Public
- Employees
- 89
- Stock Symbol
- XBIT
- Share Price
- $16.36
- (As of Friday Closing)
XBiotech General Information
Description
XBiotech Inc is a US-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing MABp1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
Contact Information
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Primary Office
- 8201 E Riverside Drive
- Building 4 Suite 100
- Austin, TX 78744
- United States
+1 (512) 000-0000
XBiotech Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $16.36 | $16.89 | $8.72 - $25.00 | $479M | 29.3M | 87.6K | $17.34 |
XBiotech Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
|---|---|---|---|---|
| EV | 323,700 | 726,545 | 161,115 | 100,648 |
| Revenue | 38,728 | 0 | 0 | 0 |
| EBITDA | 725,289 | 720,250 | (19,105) | (32,020) |
| Net Income | 677,112 | 668,629 | (21,138) | (33,150) |
| Total Assets | 353,393 | 816,877 | 44,345 | 62,972 |
| Total Debt | 0 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
XBiotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore XBiotech‘s full profile, request access.
Request a free trialXBiotech Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
XBiotech Inc is a US-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Hu
Biotechnology
Austin, TX
89
As of 2020
0000
0000
0000-00-00
00000000
0000
0000 000
quat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla p
0000000000000
Cambridge, MA
000
As of 0000
00000
0000
0000-00-00
00000000
00000
000 0000
ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
0000 000000000
Epalinges, Switzerland
000
As of 0000
00.000
00000000
00.000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialXBiotech Competitors (88)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TCR2 Therapeutics | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 00000000 | 00000 |
| 000 000000000000 | Formerly VC-backed | Epalinges, Switzerland | 000 | 00.000 | 00000000 | 00.000 |
| 0000000 | Formerly PE-Backed | Beijing, China | 0000 | 00.000 | 00000000000 | 00.000 |
| 000000000 00000000 | Formerly VC-backed | San Francisco, CA | 000 | 00000 | 000000&0 | 00000 |
| 00000 | Venture Capital-Backed | Cambridge, United Kingdom | 000 | 00000 | 000000&0 | 00000 |
XBiotech Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| John Simard | Chief Executive Officer & Chairman | ||
| Sushma Shivaswamy | Chief Scientific Officer |
XBiotech Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000 000000 | XBiotech | Chief Executive Officer & Chairman | 000 0000 |
XBiotech Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial